Ivermectin 200 mcg/kg once orally on empty stomach plus Nitazoxanide 500 mg twice daily orally with meal for 6 days

COVID-19

Ivermectin plus Nitazoxanide

Standard Care

Ivermectin and Nitazoxanide Combination Therapy for COVID-19

Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope

improved breaths per minute for the patients

Serum iron in microgram/dL of the patients

Serum ferritinin microgram/L of the patients

International normalized ratio "INR" for prothrombin time of 2

CBC for lymphocyte count in cells/microliter

Mortality rate [number of dead patients/total number of treated patients]

Prof. Dr. Kamal Mohammed Okasha

Vice-President of Postgraduate Studies and Research Affairs

Tanta University

This study will be a double blind randomized controlled parallel study

200 mg of Hydroxychloroquine orally three times daily for 10 days plus 500 mg of Nitazoxanide orally twice daily for 6 days

Standard care delivered in the COVID-19 isolation hospitals.

Both hydroxychloroquine & nitazoxanide will be administered orally to participating patients

Hydroxychloroquine plus Nitazoxanide

Oxygen administered via ventilator. In addition, antipyretic "paracetamol" may be added if necessary

Standard care

Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19

Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope

a double blind randomized controlled parallel study

20ml Liposomal Bupivacaine 1.3% (13.3mg/mL), injected to the buccal mucosal graft harvest site.

No local anesthetics injected to the buccal mucosal graft harvest site

Urethral Stricture

20ml of Liposomal Bupivacaine 1.3% (13.3mg/mL)

Liposomal Bupivacaine

Urology of Virginia

Liposomal Bupivacaine To Control Post-Operative Pain Following BMG

Liposomal Bupivacaine To Control Post-Operative Pain Following Buccal Mucosal Graft Harvesting

Continuous variables to be assessed as: Post-operative oral pain score measured using 10 point visual analogue score for pain assessment (minimum 0 or no pain to maximum 10 most painful)

Continuous variable to be assessed as : Narcotics requested by the patient and administered post-procedural day 1 and day 2 (Total and separately assessed). All narcotics will be converted to IV morphine equianalgesic equivalent conversion factors according to American Pain Society

Event rate nominal variable to be assessed as: oral morbidity post-procedure categorized according to Clavien Dindo-Classification

Event rate nominal variable to be assessed using survey question (yes or no)

Event rate nominal variable to be assessed using survey question (more, less or none)

Patient blinded for the intraoperative intervention given (With Liposomal Bupivacaine injection to the buccal mucosal graft harvest site or not)

Anaesthesia

receive intravenous injection of 0.2 mL/kg of saline 0.9%L [group P]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.

Placebo [group P]

receive intravenous injection of 0.2 mL/kg of aminophylline 10 mg/mL [group A2]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.

0.2 mL/kg of aminophylline 10 mg/mL [group A2]

receive intravenous injection of 0.2 mL/kg of aminophylline 15 mg/mL [group A3]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.

0.2 mL/kg of aminophylline 15 mg/mL [group A3]

receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL [group A4]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.

0.2 mL/kg of aminophylline 20 mg/mL [group A4]

receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL [group A5]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.

0.2 mL/kg of aminophylline 25 mg/mL [group A5]

receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL [group D]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.

Doxapram 1 mg/kg [group D]

King Faisal University

Aminophylline and Cognitive Function After Sevoflurane Anaesthesia

Aminophylline Improves Early Postoperative Cognitive Recovery After Sevoflurane Anaesthesia: A Dose-Dependent Study

The SOMCT is a patient-based test designed to assess cognitive function in terms of level of orientation, memory, and concentration.

tremor/hypoxia

Ivermectin and Nitazoxanide Combination Therapy for COVID-19

Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19

Liposomal Bupivacaine To Control Post-Operative Pain Following BMG

Aminophylline and Cognitive Function After Sevoflurane Anaesthesia

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen